The online version of this article (https://doi.org/10.1007/s11307-018-1200-4) contains supplementary material, which is available to authorized users.
Positron emission tomography (PET) with Zirconium-89 (Zr-89)-labeled antibodies can be used for in vivo quantification of antibody uptake. Knowledge about measurement variability is required to ensure correct interpretation. However, no clinical studies have been reported on measurement variability of Zr-89 immuno-PET. As variability due to low signal-to-noise is part of the total measurement variability, the aim of this study was to assess noise-induced variability of Zr-89 -immuno-PET using count-reduced clinical images.
Data were acquired from three previously reported clinical studies with [89Zr]antiCD20 (74 MBq, n = 7), [89Zr]antiEGFR (37 MBq, n = 7), and [89Zr]antiCD44 (37 MBq, n = 13), with imaging obtained 1 to 6 days post injection (D0–D6). Volumes of interest (VOIs) were manually delineated for liver, spleen, kidney, lung, brain, and tumor. For blood pool and bone marrow, fixed-size VOIs were used. Original PET list mode data were split and reconstructed, resulting in two count-reduced images at 50 % of the original injected dose (e.g., 37 MBq74inj).
Repeatability coefficients (RC) were obtained from Bland-Altman analysis on standardized uptake values (SUV) derived from VOIs applied to these images.
The RC for the combined manually delineated organs for [89Zr] antiCD20 (37 MBq74inj) increased from D0 to D6 and was less than 6 % at all time points. Blood pool and bone marrow had higher RC, up to 43 % for 37 MBq74inj at D6. For tumor, the RC was up to 42 % for [89Zr]antiCD20 (37 MBq74inj). For [89Zr]antiCD20, (18 MBq74inj), [89Zr]antiEGFR (18 MBq37inj), and [89Zr]antiCD44 (18 MBq37inj), measurement variability was independent of the investigated antibody.
Based on this study, noise-induced variability results in a RC for Zr-89-immuno-PET (37 MBq) around 6 % for manually delineated organs combined, increasing up to 43 % at D6 for blood pool and bone marrow, assuming similar biodistribution of antibodies. The signal-to-noise ratio leads to tumor RC up to 42 %.
ESM 1 (PDF 550 kb)11307_2018_1200_MOESM1_ESM.pdf
Pandit-Taskar N, O’Donoghue JA, Beylergil V, et al (2014) 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging 41:2093–2105
Armstrong IS, James JM, Williams HA, et al (2015) The assessment of time-of-flight on image quality and quantification with reduced administered activity and scan times in 18F-FDG PET. Nucl Med Commun 36:728–737
Bruijnen S, Tsang-A-Sjoe M, Raterman H, et al (2016) B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients. Arthritis Res Ther 18:266
Hagens MH, Killestein J, Yaqub MM, et al (2017) Cerebral rituximab uptake in multiple sclerosis: a 89Zr-immunoPET pilot study. Mult Scler Apr 1. https://doi.org/10.1177/1352458517704507
Jauw YWS, Zijlstra JM, de Jong D, et al (2017) Performance of 89Zr-labelled-rituximab-PET as an imaging biomarker to assess CD20 targeting: a pilot study in patients with relapsed/refractory diffuse large B cell lymphoma. PLoS One 12:e0169828
Menke-van der Houven van Oordt CW, Gootjes EC, Huisman MC, et al (2015) 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget 30:30384–30393
Menke-van der Houven van Oordt CW, Gomez-Roca C, van Herpen C, et al (2016) First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumours. Oncotarget 43:80046–80058
Makris NE, Boellaard R, Visser EP, et al (2014) Multicenter harmonization of 89Zr PET/CT performance. J Nucl Med 55:264–267
Giavarina D (2015) Understanding Bland Altman analysis. Biochem Med 25:141–151 CrossRef
Nunnally JC (1994) Psychometric theory, 3rd edn. McGraw-Hill, New York
Klettering P, Maaß C, Reske S, et al (2015) Physiologically based pharmacokinetic modeling is essential in 90Y-labelled anti-CD66 radioimmunotherapy. PLoS One 5:e0127934 CrossRef
Jauw Y, Hoekstra O, Mulder E, et al (2016) Inter-observer agreement for tumour uptake quantification of 89Zr-labelled anti-CD20 antibodies with PET. J Nucl Med 57(Suppl 2):1412
Lodge MA (2017) Repeatability of standardized uptake value in oncologic 18F-FDG PET. J Nucl Med. 2017. https://doi.org/10.2967/jnumed.116.186353
Kramer GM, Frings V, Hoetjes N, et al (2016) Repeatability of quantitative whole-body 18F-FDG PET/CT uptake measures as function of uptake interval and lesion selection in non-small cell lung cancer patients. J Nucl Med 30:1343–1349 CrossRef
Hoekstra CJ, Hoekstra OH, Stroobants SG, et al (2002) Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 43:1304–1309
Gaykema SB, Schroder CP, Vitfell-Rasmussen J, et al (2014) 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. Clin Can Res 20:3945–3954
Lartizien C, Aubin J-B, Buvat I (2010) Comparison of bootstrap resampling methods for 3-D PET imaging. IEEE Trans Med Img 29:1442–1454 CrossRef
- Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images
Yvonne W. S. Jauw
Dennis F. Heijtel
Josée M. Zijlstra
Otto S. Hoekstra
Henrica C. W. de Vet
Danielle J. Vugts
Henk M. Verheul
Guus A. M. S. van Dongen
C. Willemien Menke-van der Houven van Oordt
Adriaan A. Lammertsma
Marc C. Huisman
- Springer International Publishing
Molecular Imaging and Biology
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
Neu im Fachgebiet Radiologie
Meistgelesene Bücher aus der Radiologie
e.Med Kampagnen-Visual, Mail Icon II